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Objectives: Direct observation of health care processes through time and motion 
(T&M) studies is increasingly warranted to provide evidence of medication or device 
efficiency. This methodology can be leveraged to collect comprehensive data on 
patient characteristics, and health and care process outcomes. A hybrid T&M plus 
patient survey & chart review study design is described through case study presen-
tation and summary of lessons learned. MethOds: A prospective, observational, 
hybrid T&M study of subcutaneous immunotherapy (SCIT) administration was 
conducted at 12 sites (US and Canada). Process time and supplies consumed were 
collected through observation of SCIT visits and serum preparation. Chart reviews 
provided medical history and resource utilization; trained observers collected soci-
odemographics, loss of productivity, medication use, and travel time by survey. 
Site staff estimated time for administrative tasks related to SCIT. Results: Key 
considerations for study design and CRF development: comprehensive care process 
mapping and minimization of patient/site burden, handling treatment process vari-
ability, and maximizing generalizability of results. Site and observer recruitment, 
minimizing impact on treatment delivery, and ensuring uniformity of data col-
lection methods across sites were main operational considerations. An extensive 
study planning process along with nurse observers utilized for data collection led 
to successful completion of the study at six sites/country (primary care, allergists, 
otolaryngologists), with 670 patients. The final robust dataset consisted of observed 
treatment delivery steps and timings for staff and patients at SCIT visits (2-8 and 
4-32 min respectively, plus 2-33 min post-injection wait), patient-reported travel 
times (34-50 minutes), and detailed information regarding number/type of aller-
gens per patient through chart review. cOnclusiOns: T&M methodology allows 
for prospective data collection of observed processes, providing data on process 
efficiency and cost drivers that are often otherwise unavailable. This approach can 
be successfully combined with medical chart review and patient and site question-
naires to optimize evidence generation.
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Objectives: To understand how registries are being utilized in current post-market-
ing research. MethOds: A targeted search was conducted in MEDLINE to identify 
all original research published in 2013 reporting results from registries. The search 
was restricted to English language publications. Abstracts of relevant citations were 
reviewed to obtain the country of study, therapeutic area and registry design. A 
supplementary search of registries listed on clinicaltrials.govwas conducted to esti-
mate the number of registries currently ongoing. Results: The search returned 
136 citations, containing 128 citations reporting results from 116 unique registries. 
Amongst the 116 registries, n= 43 (37.1%) were conducted in Europe, n= 40 (34.5%) in 
the United States, n= 25 (19.8%) in Asia-Pacific and n= 5 (4.3%) multi-nationally. Most 
registries were studies in cardiology (n= 76 [65.5%]), and n= 9 (7.8%) unique registries 
were devoted to the study of pediatric patient populations. 21.6% of the registries 
were designed to investigate the safety of a medical device or pharmaceutical agent, 
and another n= 34 (29.3%) aimed to evaluate clinical outcomes of surgical interven-
tions. According to clinicaltrials.gov, there are 747 registry studies that are currently 
in active recruiting, or planning status. At the time of this review, 410 registries are 
active in North America and 247 in Europe. cOnclusiOns: The purpose of the 
present review was not to perform an exhaustive summary of all registries but to 
gain a snapshot of what has been published in a given, recent year. Results of this 
review confirm that different registry designs are being used in real-world data col-
lection to meet specific research objectives, be it safety monitoring, understanding 
disease natural history or long-term clinical outcome evaluation. Further analysis 
into the study characteristics will be presented to guide stakeholders in choosing 
appropriate registry designs.
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Objectives: Increasingly, value demonstration evidence requirements cannot 
be addressed with a single data source and/or methodology. The objective of this 
research is to present, using case studies to illustrate, a strategic and step-wise 
approach for the development of optimal study designs to address research ques-
tions which warrant multiple data sources including primary or secondary sources 
of real-world data. MethOds: Steps followed in the conceptualization of designs 
that integrate multiple data sources include: the identification and prioritization 
of research questions, delineation of evidence gaps and potential data sources, 
assessment of data availability by source and feasibility of data integration, study 
synopsis development, data protection and legal reviews, and study protocol 
development. Results: In the first case example, the purpose of the study was 
to understand reasons why patients discontinue therapy for a rare disease. Due to 
the orphan drug status, multiple data sources were needed to identify and recruit 
subjects to participate in the study. A second case study combined the use of a 
patient support program database to identify potential subjects, drug dispensing 
data from a specialty pharmacy to assess medication adherence, and a longitudinal 
patient survey assessing disease activity and patient satisfaction. Finally, two stud-
ies were designed (1 observational, 1 interventional) which utilize pharmacy claims 
data to identify potential subjects and evaluate medication adherence during the 
study period. This data is linked with longitudinal patient surveys evaluating top-
ics including treatment experience, reasons for non-adherence, and experience of 
adverse events. cOnclusiOns: These case studies demonstrate a novel approach 
to study design from within a single research network, whereby data from multiple 
identified with at least 1 ICD-9 code specifying narcolepsy (NDX), each randomly 
matched to 5 controls (no NDX; n= 46,559). A sequential validation process com-
pared claims-measurable outcomes (health care utilization, 7 known narcolepsy-
associated comorbidities) in the 1 NDX population (n= 4,587) against groups having 
2-4 NDX (n= 2,894) and 5+ NDX (n= 1,831), comparing groups to each other and to 
their matched controls. Additional comparisons were made to a reference group 
with the least ambiguous symptom (cataplexy) and an NDX persisting subsequent to 
in-period diagnostic testing (n= 465). Results: 1-way ANOVA showed consistently 
higher utilization among narcolepsy patients compared to controls [all P< 0.001] 
and equivalent utilization between narcolepsy patients, irrespective of the number 
of reported NDX [all P> 0.05], except patients with 1 NDX vs. 5+ NDX (P = 0.047). 
Similarly, chi-square analysis showed high coherence in comorbidities among NDX 
groups and significant differences vs. controls. In sum, patients with a single NDX 
were highly similar to patients with more narcolepsy diagnosis codes and consist-
ently unlike control patients without narcolepsy. Statistical differences observed 
between single NDX patients and the cataplexy subgroup with in-period testing 
will be addressed. cOnclusiOns: The sequential validation process supported 
inclusion of subjects captured by a single diagnosis code in a burden of illness study. 
This approach may prove useful in developing inclusion criteria for claims-based 
studies of other rare or chronic diseases.
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Objectives: Both the FDA and the EMA accept Progression-free Survival (PFS) and 
Disease-free Survival (DFS) as appropriate surrogate outcomes for Overall Survival 
(OS) in clinical trials, but does using PFS or DFS decrease the chances of a positive 
recommendation from Health Technology Assessment (HTA) agencies? MethOds: 
HTA assessments from 10 agencies between 2005 and 2013 for 6 solid-state oncology 
conditions were analyzed. Reviews were grouped by primary outcome as follows: OS, 
PFS, co-primary outcomes, DFS and other. HTA recommendations were categorized 
as positive or negative. Results: A total of 245 reviews were analyzed. Reviews 
that did not report a primary outcome were excluded (17%). The use of primary 
outcome was highly dependent on the cancer. OS was overwhelmingly used in 
melanoma and small-cell lung cancer, while PFS was used in ovarian cancer. Due 
to the lack of variety in the primary outcome used in these cancers, rates of posi-
tive recommendations associated with the choice of primary outcome could not 
be calculated. Colorectal cancer (CC) used PFS, OS and DFS at similar rates (25%, 
26% and 22% respectively; n= 68); Non-small cell lung cancer (NSCLC) used OS and 
PFS at similar rates (44% and 36% respectively; n= 61). The majority of prostate 
cancer (PC) reviews used OS (66%), but 32% used other outcomes (mostly related to 
measuring testosterone levels; n= 38). There was no statistical difference between 
the use of outcomes and the rate of positive recommendation in CC, NSCLC or 
PC. cOnclusiOns: The choice in primary outcome was dependent on the oncology 
condition. The relationship between choice in primary outcome and reimbursement 
recommendation was not significant for oncology conditions that used a variety 
of outcomes. Further research and multivariate analysis is needed to determine if 
the choice of a surrogate outcome in oncology HTA reviews decreases the chances 
of a positive approval.
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Objectives: In the absence of randomized controlled trials (RCTs) and to verify 
RCT evidence, health technology assessment (HTA) agencies commonly rely on non-
RCTs to provide evidence of the effectiveness of health care interventions. This type 
of study design can introduce considerable bias into a systematic review and a num-
ber of methodologies exist to evaluate the risk of bias in such studies. We undertook 
a series of reviews to identify which tools are commonly used in the literature and 
in an HTA setting for critical appraisal of non-RCTs. MethOds: Firstly, a targeted 
search of systematic reviews including non-RCTs was conducted in MEDLINE and 
EMBASE (OVID SP). Studies identified were reviewed to determine which appraisal 
tool, if any, was used. Secondly, recommendations for the critical appraisal of non-
RCTs by expert review groups (Cochrane, Centre for Reviews and Disseminations 
(CRD)) and HTA bodies (including NICE, SMC, NCPE, AWMSG, IQWiG, PBAC, AMCP 
and CADTH) were reviewed. Criteria covered by each tool were recorded. Results: 
446 studies were identified by the targeted search and were screened. We identified 
a large number of critical appraisal tools. Commonly used tools included Downs & 
Black, Chalmers, the Newcastle-Ottawa Scale, and the CriSTal checklist. Neither the 
Cochrane Collaboration nor CRD recommend a particular risk of bias instrument. 
Only one HTA body, CADTH, recommend use of a specific critical appraisal tool; 
SIGN 50 (for cohort or case-control studies). The tools identified examine a vari-
ety of criteria including reporting, external validity, bias, confounding, power and 
temporal parallelism. cOnclusiOns: There is a lack of consensus on a preferred 
instrument that allows for the assessment of all types of non-RCT evidence. As a 
result, critical appraisal of non-RCTs is often omitted from HTA submissions. There 
is thus a need for cross communication between groups to reach a consensus and 
develop a suitable tool.
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